Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

PANCEP-1 Recruiting

2023-506979-10-00 Pancreatic cancer 2025-09-02
A clinical study of ifinatamab deruxtecan and pembrolizumab with or without chemotherapy in people with esophageal cancer (MK-3475-06E) Recruiting

2024-514273-22-00 Esophageal squamous cell carcinoma 2025-09-02
A clinical study of combination therapies in people with kidney cancer (MK-3475-03C) Recruiting

2024-516437-12-00 Clear cell renal cell carcinoma 2025-08-29
PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS Recruiting

2024-514954-63-00 RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS 2025-08-20
Pomalidomide in people with chronic hepatitis B virus (HBV) infection: Safety and immune-enhancing effects (The PIPPI Study) Recruiting

2025-521030-29-00 Hepatitis B virus infection 2025-08-19
Safety and Preliminary Clinical Efficacy of MT-302 with CapOx based regimens in metastatic esophagogastric cancer (SPaCE-MT) Recruiting

2024-520213-45-00 metastatic esophagogastric cancer 2025-08-15
A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting

2024-516036-94-00 Metastatic castrate resistant prostate cancer - mCRPC 2025-08-12
A Phase I/II Double-blind, randomized, placebo-controlled trial to preserve residual insulin secretion in children with recent onset Type 1 … Recruiting

2024-515106-30-00 Type 1 diabetes 2025-08-06
A phase I/II study of CAR-expressing Allogenic iPSC derived NK cells for treatment of autoiMmune disease by B cELl depletion - CARAMEL Recruiting

2024-519532-16-00 Idiopathic inflammatory myositis 2025-07-30
A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma Recruiting

2024-512146-41-00 Multiple Myeloma 2025-07-29
An open-label study to assess safety, efficacy, and cellular kinetics of YTB323 in treatment-resistant generalized myasthenia gravis Recruiting

2024-513589-20-00 Treatment-resistant generalized Myasthenia Gravis 2025-07-29
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib … Recruiting

2025-520743-33-00 Advanced/metastatic colorectal cancer 2025-07-23
A clinical trial applying Regulatory T cells in liver transplant recipients to investigate the safety and tolerability when stopping standar… Recruiting

2023-508261-32-00 Solid organ transplantation (Liver) 2025-07-21
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Patients Treated for Blood Cancers Recruiting

2024-518829-15-00 previously untreated chronic lymphocytic leukemia (CLL) 2025-07-02
A clinical study of patritumab deruxtecan (HER3-DXd) in children with cancer (MK-9999-01C) Recruiting

2024-518771-66-00 Hepatoblastoma, Rhabdomyosarcoma 2025-07-01
Phase I Study of PM534 to Patients with Advanced Solid Tumors Recruiting

2024-519013-57-00 Advances solid tumors 2025-06-23
A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren’s diseas… Recruiting

2024-514596-18-00 Difficult to treat rheumatoid arthritis 2025-06-20
A Phase 1/2a Study of BMS-986507 (BL-B01D1) in Adult Participants with Advanced Solid Tumors Recruiting

2024-514947-27-00 Advance solid tumors 2025-06-18
A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours Recruiting

2023-504246-64-02 Relapsed/refractory neuroblastoma and other solid tumou 2025-06-04
Assessment of the safety and efficacy of a hepatitis B vaccine in adult patients with hepatitis B Recruiting

2023-507623-36-00 Chronic hepatitis B 2025-05-26
A clinical study of MK-3120 in people with solid tumors (MK-3120-002) Recruiting

2024-516817-19-00 Advanced/metastatic solid tumor disease 2025-05-23
A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting

2024-517147-31-00 Tumours, Gynecological 2025-05-23
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping t… Recruiting

2024-517584-23-00 Duchenne Muscular Dystrophy 2025-05-16
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination with Cytarabine in Patie… Recruiting

2024-518071-58-00 Relapsed/refractory (r/r) acute myeloid leukemia (AML) 2025-05-16